Canton Hathaway’s Vertex Pharmaceuticals VRTX Stock Holding History

Canton Hathaway’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$32.4K	Hold	62	–	–	0.01%	239
2026 Q2	$30.8K	Hold	62	–	–	0.01%	245
2026 Q1	$27.7K	Hold	62	–	–	0.01%	238
2025 Q4	$28.1K	Hold	62	–	–	0.01%	245
2025 Q3	$24K	Hold	62	–	–	﹤0.01%	258
2025 Q2	$28K	Hold	62	–	–	0.01%	244
2025 Q1	$30K	Hold	62	–	–	0.01%	238
2024 Q4	$25K	Hold	62	–	–	0.01%	222
2024 Q3	$29K	Hold	62	–	–	0.01%	213
2024 Q2	$29K	Hold	62	–	–	0.01%	207
2024 Q1	$26K	Hold	62	–	–	0.01%	218
2023 Q4	$25K	Hold	62	–	–	0.01%	212
2023 Q3	$22K	Hold	62	–	–	0.01%	216
2023 Q2	$22K	Buy	+62	New	+$20.9K	0.01%	221

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Provident Investment Management Novi, Michigan $999M AUM 19.45% 1-Year Est. Return

Canton Hathaway's VRTX Position: Q3 2026 in Review

Canton Hathaway held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2026 at 62 shares worth $32.4K. The position accounts for 0.01% of the portfolio, ranked #239.

Canton Hathaway first reported a position in VRTX in Q2 2023 and has held it in 14 quarters since. 478 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Canton Hathaway held 62 shares of Vertex Pharmaceuticals worth $32.4K as of Q3 2026.
Canton Hathaway left its Vertex Pharmaceuticals share count unchanged in Q3 2026.
Vertex Pharmaceuticals made up 0.01% of Canton Hathaway's portfolio in Q3 2026, its #239 holding.
Canton Hathaway first reported a position in Vertex Pharmaceuticals in Q2 2023 and has held it in 14 quarters since.
478 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Canton Hathaway's 13F filing for Q3 2026, filed 23 Oct 2026.